Tanios Bekaii-Saab, MD: Not Just Seeing the Light, But Getting Out of the Tunnel
Dr. Tanios Bekaii-Saab spent time discussing the path to practicing in gastrointestinal malignancies, how he navigates balancing his professional and personal life, and mottos he has lived by throughout his career and while caring for his patients.
Welcome to a very special edition of OncLive On Air!
OncLive On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
But today, we had the pleasure of sitting down with Tanios Bekaii-Saab, MD, FACP, who is a medical oncologist, and medical director of the Cancer Clinical Research Office, vice chair and section chief of Medical Oncology in the Department of Internal Medicine, at Mayo Clinic. Saab is also on the selection committee for the OncLive Giants of Cancer Care program.
He has been a leading oncologist in the gastrointestinal cancers field, and has spearheaded several research efforts that have impacted clinical practice. such as the phase II ReDOS trial, which evaluated a weekly regorafenib dose-escalation strategy beginning at 80 mg and ending at 160 mg. Results showed that the approach was appropriate and potentially optimal for previously treated patients with metastatic colorectal cancer.
In our exclusive interview, Dr. Bekaii-Saab spent time discussing the path to practicing in gastrointestinal malignancies, how he navigates balancing his professional and personal life, and mottos he has lived by throughout his career and while caring for his patients.
